Brain delivery enabled by transient blood-brain barrier disruption induced by regadenoson: a PET imaging study.

Blood-brain barrier brain delivery immunoPET nanoparticle pharmacokinetics, positron emission tomography

Journal

Expert opinion on drug delivery
ISSN: 1744-7593
Titre abrégé: Expert Opin Drug Deliv
Pays: England
ID NLM: 101228421

Informations de publication

Date de publication:
17 Jun 2024
Historique:
medline: 17 6 2024
pubmed: 17 6 2024
entrez: 17 6 2024
Statut: aheadofprint

Résumé

Regadenoson, an agonist of adenosine A2 receptors, enables transient blood-brain barrier (BBB) disruption. The relevance of regadenoson as a pharmacological strategy for brain delivery was investigated using in vivo PET imaging in rats. Kinetic modeling of brain PET data was performed to estimate the impact of regadenoson (0.05 mg.kg Regadenoson significantly increased the BBB penetration (+116 ± 13%, PET imaging showed the features and limitations of BBB disruption induced by regadenoson in terms of extent, regional distribution, and reversibility. Nevertheless, regadenoson enables the brain delivery of small molecules or nanoparticles in rats.

Sections du résumé

BACKGROUND UNASSIGNED
Regadenoson, an agonist of adenosine A2 receptors, enables transient blood-brain barrier (BBB) disruption. The relevance of regadenoson as a pharmacological strategy for brain delivery was investigated using in vivo PET imaging in rats.
RESEARCH DESIGN AND METHODS UNASSIGNED
Kinetic modeling of brain PET data was performed to estimate the impact of regadenoson (0.05 mg.kg
RESULTS UNASSIGNED
Regadenoson significantly increased the BBB penetration (+116 ± 13%,
CONCLUSIONS UNASSIGNED
PET imaging showed the features and limitations of BBB disruption induced by regadenoson in terms of extent, regional distribution, and reversibility. Nevertheless, regadenoson enables the brain delivery of small molecules or nanoparticles in rats.

Identifiants

pubmed: 38881261
doi: 10.1080/17425247.2024.2369765
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Benoit Hosten (B)

Université Paris-Saclay, Inserm, CNRS, CEA, Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Service Hospitalier Frédéric Joliot, France.
INSERM UMR1144, Université Paris Cité, PARIS, France.

Sébastien Goutal (S)

Université Paris-Saclay, Inserm, CNRS, CEA, Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Service Hospitalier Frédéric Joliot, France.

Sarah Leterrier (S)

Université Paris-Saclay, Inserm, CNRS, CEA, Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Service Hospitalier Frédéric Joliot, France.

Cassandre Corvo (C)

Université Paris-Saclay, Inserm, CNRS, CEA, Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Service Hospitalier Frédéric Joliot, France.

Louise Breuil (L)

Université Paris-Saclay, Inserm, CNRS, CEA, Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Service Hospitalier Frédéric Joliot, France.
INSERM UMR1144, Université Paris Cité, PARIS, France.

Olivier Barret (O)

CEA, CNRS, Université Paris-Saclay, MIRCen, Laboratoire des Maladies Neurodégénératives, Fontenay-Aux-Roses, France.

Simon Specklin (S)

Université Paris-Saclay, Inserm, CNRS, CEA, Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Service Hospitalier Frédéric Joliot, France.

Charles Truillet (C)

Université Paris-Saclay, Inserm, CNRS, CEA, Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Service Hospitalier Frédéric Joliot, France.

Nicolas Tournier (N)

Université Paris-Saclay, Inserm, CNRS, CEA, Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Service Hospitalier Frédéric Joliot, France.

Classifications MeSH